U.S. flag

An official website of the United States government

NM_000152.5(GAA):c.308G>A (p.Cys103Tyr) AND Glycogen storage disease, type II

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Dec 14, 2020
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002045222.5

Allele description [Variation Report for NM_000152.5(GAA):c.308G>A (p.Cys103Tyr)]

NM_000152.5(GAA):c.308G>A (p.Cys103Tyr)

Gene:
GAA:alpha glucosidase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_000152.5(GAA):c.308G>A (p.Cys103Tyr)
HGVS:
  • NC_000017.11:g.80104894G>A
  • NG_009822.1:g.8339G>A
  • NM_000152.5:c.308G>AMANE SELECT
  • NM_001079803.3:c.308G>A
  • NM_001079804.3:c.308G>A
  • NP_000143.2:p.Cys103Tyr
  • NP_001073271.1:p.Cys103Tyr
  • NP_001073272.1:p.Cys103Tyr
  • LRG_673:g.8339G>A
  • NC_000017.10:g.78078693G>A
Protein change:
C103Y
Links:
dbSNP: rs2143827215
NCBI 1000 Genomes Browser:
rs2143827215
Molecular consequence:
  • NM_000152.5:c.308G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001079803.3:c.308G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001079804.3:c.308G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Glycogen storage disease, type II (GSD2)
Synonyms:
ACID ALPHA-GLUCOSIDASE DEFICIENCY; GLYCOGENOSIS, GENERALIZED, CARDIAC FORM; GSD II; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0009290; MedGen: C0017921; Orphanet: 365; OMIM: 232300

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002295958Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely pathogenic
(Dec 14, 2020)
germlineclinical testing

PubMed (7)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Late form of Pompe disease with glycogen storage in peripheral nerves axons.

Fidziańska A, Ługowska A, Tylki-Szymańska A.

J Neurol Sci. 2011 Feb 15;301(1-2):59-62. doi: 10.1016/j.jns.2010.10.031. Epub 2010 Nov 25.

PubMed [citation]
PMID:
21109266

Pompe disease in Austria: clinical, genetic and epidemiological aspects.

Löscher WN, Huemer M, Stulnig TM, Simschitz P, Iglseder S, Eggers C, Moser H, Möslinger D, Freilinger M, Lagler F, Grinzinger S, Reichhardt M, Bittner RE, Schmidt WM, Lex U, Brunner-Krainz M, Quasthoff S, Wanschitz JV.

J Neurol. 2018 Jan;265(1):159-164. doi: 10.1007/s00415-017-8686-6. Epub 2017 Nov 27.

PubMed [citation]
PMID:
29181627
PMCID:
PMC5760608
See all PubMed Citations (7)

Details of each submission

From Invitae, SCV002295958.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (7)

Description

In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Cys103 amino acid residue in GAA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 21109266, 29181627, 18429042, 18607768, 14695532, 24158270). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GAA protein function. This variant has not been reported in the literature in individuals with GAA-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces cysteine with tyrosine at codon 103 of the GAA protein (p.Cys103Tyr). The cysteine residue is highly conserved and there is a large physicochemical difference between cysteine and tyrosine.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Mar 5, 2024